Response to Treatment of Hepatitis C in Individuals With a Recent History of Intravenous Drug Abuse

American Journal of Gastroenterology

Volumn 98, Issue 10, 2003, Pages 2281-2288

  Van Thiel, David H ^a,b   Anantharaju, Abhinandana ^a   Creech, Steven ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Building 114 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; INTERFERON; METHADONE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0142214795     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(03)00708-1     Document Type: Article

References (23)

1. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:25-95.
2. Liang TJ, Rehermann D, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
3. Edlin BR, Seal KH, Kral AH. Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Engl Med 2001;345:211-14.
4. Normand J, Vlahou D, Moses LE. Preventing HIV transmission: The role of sterile needles and bleach. Washington, DC: National Academy Press 1995.
5. Thomas DL, Vlahou D, Soloman L, et al. Correlates of hepatitis C infection among injection drug users. Medicine (Baltimore) 1995;74:212-20.
6. Lorwick J, Kral AH, Seal H, et al. Prevalence and duration of hepatitis C among injection drug users in San Francisco Calif. Am J Public Health 2001;91:46-7.
7. Management of hepatitis C. National Institutes of Health consensus statement, vol. 15, no 3. Bethesda, MD: National Institute of Health 1997.
8. Stephanson J. Former addicts face barrier to treatment for HCV. JAMA 2001;285:1003-5.
9. EASL International Consensus Conference in Hepatitis C. Consensus statement. J Hepatol 1999;30:956-61.
10. Sherman M. Management of viral hepatitis: Clinical and public health perspective-a consensus statement. Can J Gastroenterol 1997;11:407-6.
11. Gerstin DR, Harwood HJ. Treating drug problems. Washington, DC: National Academy Press, 1990.
12. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001;345:215-7.
13. Gurakar A, Fagiuoli S, Faruki H, et al. Utility of hepatitis C virus RNA determinations in hepatic tissue as an end point for interferon treatment of chronic hepatitis C. Hepatology 1995; 22:1109-12.
14. Van Thiel DH, Careceni P, Molloy PJ, et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: The role of interferon α2b therapy. J Hepatol 1995;23:503-8.
15. Colantoni A, De Maria N, Idilman R, Villa E, Manenti F, Van Thiel DH. Treatment of chronic hepatitis C virus infection in the elderly with high dose interferon. Gerontology (in press).
16. De Maria N, Colantoni A, Idilman R, et al. Impaired response to high dose interferon treatment in African-Americans with chronic hepatitis C. Hepato-Gastroenterol 2002;49:788-92.
17. Srinivas D, Mani H, Crumpler C, Van Thiel DH. Daily interferon therapy for chronic hepatitis C: A report of community experience. Hepato-Gastroenterol 2002;49:1053-7.
18. Friedlander L, Van Thiel DH, Faruki H, et al. New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease. Dig Dis Sci 1996; 41:1678-81.
19. Goodman JJ, Jeffers LJ, Bernstein DE, et al. Hepatitis C in alcoholic patients with and without clinically apparent liver disease. Alcohol Clin Exp Res 1995;19:1173-6.
20. De Maria N, Colantoni A, Friedlander L, et al. The impact of prior HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000;95:3529-36.
21. Mehta SH, Cox A, Hoover DR, et al. Protection against hepatitis C persistence. Lancet 2002;359:1478-83.
22. Sylvester D, Clements B. Treating hepatitis C in methadone maintenance patients. Atlanta, GA: American Society of Addiction Medicine, 2002.
23. Backmund M, Meyer K, VanZielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-93.